PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
PERRIGO Co plc
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$16.09−0.54 (-3.25%)
Close on Oct 19, 2026
- Market cap
- $2.25B
- P/E (TTM)
- –
- Dividend yield
- 7.21%
PERRIGO Co plc revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCA | $2.59B | $2.69B | $2.96B | $2.93B | $2.69B | $2.69B | $2.49B | $2.41B | $2.43B | – | 60.8% | -4.0% |
| CSCI | $1.67B | $1.68B | $1.69B | $1.53B | $1.45B | $1.40B | $1.38B | $1.40B | $1.41B | – | 39.2% | -0.7% |
| Other(1) | – | – | – | – | – | – | $0 | $0 | $55.70M | $107.70M | – | – |
| Segment Reconciling Items | – | – | – | – | – | – | $0 | $0 | – | $0 | – | – |
| CHCA | – | – | – | – | – | – | – | – | – | $2.75B | – | – |
| RX | – | – | – | – | – | – | – | – | – | $936.00M | – | – |
| Specialty Sciences | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| CHCI | – | – | – | – | – | – | – | – | – | $704.60M | – | – |
| CHCA [Member] | – | – | – | – | – | – | – | – | – | $2.48B | – | – |
| CHCI | – | – | – | – | – | – | – | $1.50B | $1.49B | $704.60M | – | – |
| CHCA | – | – | – | – | – | – | – | $2.41B | $2.43B | $2.48B | – | – |
| RX Pharmaceuticals | – | – | $0 | $0 | $0 | $0 | $0 | $920.80M | $1.05B | $936.00M | – | – |
| All Countries Domain | – | – | – | – | – | – | – | – | – | $4.60B | – | – |
| All Countries | – | – | – | – | – | – | – | – | – | $4.23B | – | – |
| Other | – | – | – | – | – | – | $0 | $0 | $55.70M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CSCI | -$228.80M | $105.00M | -$35.20M | -$30.00M | $36.10M | $32.30M | $19.60M | $6.80M | -$2.70M | – | -317.9% |
| CSCA | -$669.00M | $269.90M | $389.60M | $366.10M | $206.50M | $465.00M | $406.70M | $174.40M | $470.90M | – | -347.9% |
| Other(1) | – | – | – | – | – | – | $0 | $0 | $8.70M | $26.80M | – |
| Segment Reconciling Items | – | – | – | – | – | – | -$231.40M | -$159.30M | -$175.60M | -$121.50M | – |
| CHCA | – | – | – | – | – | – | – | – | – | $405.60M | – |
| RX | – | – | – | – | – | – | – | – | – | $364.70M | – |
| Specialty Sciences | – | – | – | – | – | – | – | – | $0 | -$17.60M | – |
| CHCI | – | – | – | – | – | – | – | – | – | $38.20M | – |
| CHCA [Member] | – | – | – | – | – | – | – | – | – | $381.90M | – |
| CHCI | – | – | – | – | – | – | – | $16.50M | $12.50M | $38.20M | – |
| CHCA | – | – | – | – | – | – | – | $147.60M | $445.00M | $381.90M | – |
| RX Pharmaceuticals | – | – | $0 | $0 | $0 | $0 | $0 | $214.60M | $306.10M | $364.70M | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing | $270.90M | $306.20M | $337.30M | $350.10M | $299.70M | $261.40M | $285.30M | $300.50M | – | – | 6.4% | -11.5% |
| Active pharmaceutical ingredients | – | – | – | – | – | – | – | $0 | $55.60M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.54B | $2.65B | $2.92B | $2.87B | $2.57B | $2.58B | $2.36B | $3.10B | $3.27B | $3.30B | 59.7% | -4.1% |
| Europe | $1.62B | $1.60B | $1.62B | $1.47B | $1.39B | $1.35B | $1.34B | $1.35B | $1.34B | $576.40M | 38.0% | +0.7% |
| All other countries | $96.70M | $119.50M | $116.30M | $107.30M | $179.80M | $158.60M | $173.80M | $285.80M | $330.30M | – | 2.3% | -19.1% |
| Ireland | $42.10M | $39.60M | $40.80M | $29.30M | $23.70M | $29.80M | $23.40M | $25.70M | $30.40M | $7.20M | 1.0% | +6.3% |
| Outside United States [Member] | – | – | – | – | – | – | – | – | – | $340.30M | – | – |
| All other countries | – | – | – | – | – | – | – | – | $330.30M | $340.30M | – | – |
From the segment and revenue-disaggregation notes of Perrigo's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.